VIVUS, Inc.  

(Public, NASDAQ:VVUS)   Watch this stock  
Find more results for VVUS
1.41
-0.10 (-6.62%)
Real-time:   1:40PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.41 - 1.52
52 week 1.28 - 4.89
Open 1.50
Vol / Avg. 779,681.00/1.13M
Mkt cap 147.36M
P/E     -
Div/yield     -
EPS -0.80
Shares 103.81M
Beta 1.48
Inst. own 67%
Jul 30, 2015
Q2 2015 VIVUS Inc Earnings Call - Webcast
Jul 30, 2015
Q2 2015 VIVUS Inc Earnings Release
May 5, 2015
Q1 2015 VIVUS Inc Earnings Call - Webcast
May 5, 2015
Q1 2015 VIVUS Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -48.08% -72.38%
Operating margin -21.21% -44.41%
EBITD margin - -38.03%
Return on average assets -17.19% -20.69%
Return on average equity -82.06% -70.07%
Employees 94 -
CDP Score - -

Address

351 E Evelyn Ave
MOUNTAIN VIEW, CA 94041-1530
United States - Map
+1-650-9345200 (Phone)
+1-650-9345389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Officers and directors

David York Norton Chairman of the Board and Director
Age: 63
Bio & Compensation  - Reuters
Seth H. Z. Fischer Chief Executive Officer, Chief Commercial Officer, Director
Age: 59
Bio & Compensation  - Reuters
Svai S. Sanford Chief Financial Officer, Chief Accounting Officer
Age: 45
Bio & Compensation  - Reuters
John L. Slebir Esq. Senior Vice President - Business Development, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Guy P. Marsh Vice President - U.S. Operations, General Manager
Age: 61
Bio & Compensation  - Reuters
Wesley W. Day Ph.D. Vice President - Clinical Development
Age: 51
Bio & Compensation  - Reuters
Santosh T. Varghese M.D Vice President-Medical & Regulatory Affairs, Pharmacovigilance, and QA
Age: 44
Bio & Compensation  - Reuters
Alexander J. Denner Ph.D. Director
Age: 45
Bio & Compensation  - Reuters
Herman Rosenman CPA Director
Age: 67
Bio & Compensation  - Reuters
Jorge Plutzky M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters